Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.

A user is considering a serum with Redensyl, Anagain, and Procapil for male pattern baldness. They are asking if it will be effective.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

41-year-old female experienced slow hair thinning, took finasteride for a year, then switched to spironolactone. Irregular periods occurred, seeking advice on long-term side effects and considering a third medication.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.

Akkermansia bacteria can improve hair growth inhibited by testosterone, and metformin may increase Akkermansia, which could help with hair loss related to aging, insulin resistance, and inflammation.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

The conversation warns against buying RU58841 from Amazon due to concerns about product authenticity and recommends purchasing from trusted sources like Minoxidilmax and Anageninc.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

Topical 1% cetirizine is more effective for hair growth than 10 mg oral cetirizine. It can be ordered online from specific hair loss companies.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.